ArticleScientific reports2025
Exercise training and Silymarin consumption can ameliorate mitophagy signaling flux in hepatocytes of rats with dexamethasone-induced non-alcoholic fatty liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Exercise and dietary interventions in the regulation of hepatic mitophagy and liver recovery (Review).Biomedical reports · 2026Review
- The Protective Effect of Naringenin against Lead-Induced Hepatotoxicity in Rats: Mechanisms Involving Oxidative Stress Mitigation, Activation of PINK1/Parkin and Nrf2/NQO1 Pathways, and Autophagy Induction.Biological trace element research · 2026Article
- Research Progress and Prospects of Flavonoids in the Treatment of Diseases by Regulating Autophagy: A Narrative Review.Molecules (Basel, Switzerland) · 2026Review
- Apigenin combined with aerobic exercise alleviates oxidative stress and inflammation in high-fat diet-induced NAFLD mice by modulating the Keap1/Nrf2/ARE pathway.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to investigate the effects of exercise training combined with silymarin supplementation on mitophagy markers in hepatocytes of rats with dexamethasone-induced non-alcoholic fatty liver disease (NAFLD). Forty-two male Wistar rats (6 weeks old) were divided into 7 groups (n = 6 per group): 1- Control (CON), 2- Dexamethasone (DEX), 3- DEX + moderate-intensity training (DEX-MIT), 4- DEX + high intensity training (DEX-HIT), 5- DEX + silymarin (DEX-S), 6- DEX + moderate intensity training + silymarin (DEX-MIT-S), 7- DEX-high intensity training + silymarin (DEX-HIT-S). NAFLD was induced by subcutaneous administration of dexamethasone for 7 days. Exercise groups underwent 8 weeks of treadmill running (5 sessions/week) at matched distances for MIT and HIT protocols. Silymarin was administered via oral gavage at a dose of 300 mg/kg body weight/day. Gene expression levels of mTORC1, AMPKα2, Bcl-2, Parkin, and LC3 were measured using real-time PCR. Protein levels of PINK1, Beclin-1, and P62 were assessed by western blotting. Moderate and high intensity training significantly reduced Bcl-2 and LC3 gene expression and increased P62 protein levels compared to the DEX group (P < 0.05). Silymarin supplementation significantly decreased expression of Parkin, Bcl-2, LC3, and PINK1 compared to the DEX (P < 0.05). Bcl-2 and LC3 gene expressions were lower in DEX-MIT-S and DEX-HIT-S compared to DEX (P < 0.05). PINK1 levels were reduced in the DEX-MIT-S relative to DEX (P < 0.05). LC3 gene expression was higher in DEX-HIT-S compared to DEX-MIT-S (P < 0.05). The findings suggest that both exercise training and silymarin supplementation can attenuate excessive mitophagy signaling in hepatocytes of rats with dexamethasone-induced NAFLD, potentially providing hepatoprotective effects against further damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.